An evaluation of avatrombopag for the treatment of thrombocytopenia

References

• Haznedaroglu IC, Goker H, Turgut M, et al. Thrombopoietin as a drug: biologic expectations, clinical realities, and future directions. Clin Appl Thromb Off J Int Acad Clin Appl Thromb. 2002;8(3):193–212.
   PubMed Web of Science ®Google Scholar
• Al-Samkari H, Kuter DJ. Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia. Ther Adv Hematol. 2019;10:2040620719841735.
   Web of Science ®Google Scholar
• Kuter DJ. The biology of thrombopoietin and thrombopoietin receptor agonists. Int J Hematol. 2013;98(1):10–23.
   PubMed Web of Science ®Google Scholar
• Kuter DJ, Rummel M, Boccia R, et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med. 2010;363(20):1889–1899.
   PubMed Web of Science ®Google Scholar
• Al-Samkari H, Grace RF, Kuter DJ. The role of romiplostim for pediatric patients with immune thrombocytopenia. Ther Adv Hematol. 2020;11:2040620720912992.
   Web of Science ®Google Scholar
• Terrault N, Chen Y-C, Izumi N, et al. Avatrombopag before procedures reduces need for platelet transfusion in patients with chronic liver disease and thrombocytopenia. Gastroenterology. 2018;155(3):705–718.
   PubMed Web of Science ®Google Scholar
• Al-Samkari H, Marshall AL, Goodarzi K, et al. Romiplostim for the management of perioperative thrombocytopenia. Br J Haematol. 2018;182(1):106–113.
   PubMed Web of Science ®Google Scholar
• Nagrebetsky A, Al-Samkari H, Davis NM, et al. Perioperative thrombocytopenia: evidence, evaluation, and emerging therapies. Br J Anaesth. 2019;122(1):19–31.
   PubMed Web of Science ®Google Scholar
• Al-Samkari H, Marshall AL, Goodarzi K, et al. The use of romiplostim in treating chemotherapy-induced thrombocytopenia in patients with solid tumors. Haematologica. 2018;103(4):e169–e172.
   PubMed Web of Science ®Google Scholar
• Soff GA, Miao Y, Bendheim G, et al. Romiplostim treatment of chemotherapy-induced thrombocytopenia. J Clin Oncol Off J Am Soc Clin Oncol. 2019;37(31):2892–2898.
   PubMed Web of Science ®Google Scholar
• Al-Samkari H, Parnes AD, Goodarzi K, et al. A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies. Haematologica. 2020 Jun 4. DOI:10.3324/haematol.2020.251900
   PubMed Web of Science ®Google Scholar
• Townsley DM, Scheinberg P, Winkler T, et al. Eltrombopag added to standard immunosuppression for aplastic anemia. N Engl J Med. 2017;376(16):1540–1550.
   PubMed Web of Science ®Google Scholar
• Afdhal NH, Dusheiko GM, Giannini EG, et al. Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy. Gastroenterology. 2014;146(2):442–452.e1.
   PubMed Web of Science ®Google Scholar
• Cheloff AZ, Al-Samkari H. Avatrombopag for the treatment of immune thrombocytopenia and thrombocytopenia of chronic liver disease. J Blood Med. 2019;10:313–321.
   PubMed Web of Science ®Google Scholar
• Keating GM. Romiplostim: a review of its use in immune thrombocytopenia. Drugs. 2012;72(3):415–435.
   PubMed Web of Science ®Google Scholar
• Gómez-Almaguer D. Eltrombopag-based combination treatment for immune thrombocytopenia. Ther Adv Hematol. 2018;9(10):309–317.
   PubMed Web of Science ®Google Scholar
• Peck-Radosavljevic M, Simon K, Iacobellis A, et al. Lusutrombopag for the treatment of thrombocytopenia in patients with chronic liver disease undergoing invasive procedures (L-PLUS 2). Hepatology. 2019;70(4):1336–1348.
   PubMed Web of Science ®Google Scholar
• Shirley M, McCafferty EH, Blair HA. Lusutrombopag: a review in thrombocytopenia in patients with chronic liver disease prior to a scheduled procedure. Drugs. 2019;79(15):1689–1695.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. FDA approves avatrombopag for thrombocytopenia in adults with chronic liver disease. FDA; 2019 Feb 9 [cited 2020 Jun 25]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-avatrombopag-thrombocytopenia-adults-chronic-liver-disease
   Google Scholar
• Avatrombopag Prescribing Information. Drugs@FDA: FDA-approved drugs; [ cited 2020 Jun 25]. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process
   Google Scholar
• Jurczak W, Chojnowski K, Mayer J, et al. Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia. Br J Haematol. 2018;183(3):479–490.
   PubMed Web of Science ®Google Scholar
• Clemons Bankston P, Al-Horani RA. New small molecule drugs for thrombocytopenia: chemical, pharmacological, and therapeutic use considerations. Int J Mol Sci. 2019;20(12). DOI:10.3390/ijms20123013
   PubMed Web of Science ®Google Scholar
• Al-Samkari H. Avatrombopag maleate for the treatment of periprocedural thrombocytopenia in patients with chronic liver disease. Drugs Today Barc Spain 1998. 2018;54(11):647–655.
   Google Scholar
• Kuter DJ. New thrombopoietic growth factors. Blood. 2007;109(11):4607–4616.
   PubMed Web of Science ®Google Scholar
• Fukushima-Shintani M, Suzuki K, Iwatsuki Y, et al. AKR-501 (YM477) a novel orally-active thrombopoietin receptor agonist. Eur J Haematol. 2009;82(4):247–254.
   PubMed Web of Science ®Google Scholar
• Fukushima-Shintani M, Suzuki K, Iwatsuki Y, et al. AKR-501 (YM477) in combination with thrombopoietin enhances human megakaryocytopoiesis. Exp Hematol. 2008;36(10):1337–1342.
   PubMed Web of Science ®Google Scholar
• Nomoto M, Pastino G, Rege B, et al. Pharmacokinetics, pharmacodynamics, pharmacogenomics, safety, and tolerability of avatrombopag in healthy Japanese and white subjects. Clin Pharmacol Drug Dev. 2018;7(2):188–195.
   PubMed Web of Science ®Google Scholar
• Nomoto M, Ferry J, Hussein Z. Population pharmacokinetic/pharmacodynamic analyses of avatrombopag in patients with chronic liver disease and optimal dose adjustment guide with concomitantly administered CYP3A and CYP2C9 inhibitors. J Clin Pharmacol. 2018;58(12):1629–1638.
   PubMed Web of Science ®Google Scholar
• Al-Samkari H, Kuter DJ. Thrombopoietin level predicts response to treatment with eltrombopag and romiplostim in immune thrombocytopenia. Am J Hematol. 2018;93(12):1501–1508.
   PubMed Web of Science ®Google Scholar
• Jenkins JM, Williams D, Deng Y, et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood. 2007;109(11):4739–4741.
   PubMed Web of Science ®Google Scholar
• Al-Samkari H, Kuter DJ. Relative potency of the thrombopoietin receptor agonists eltrombopag, avatrombopag and romiplostim in a patient with chronic immune thrombocytopenia. Br J Haematol. 2018;183(2):168.
   PubMed Web of Science ®Google Scholar
• Wire MB, Bruce J, Gauvin J, et al. A randomized, open-label, 5-period, balanced crossover study to evaluate the relative bioavailability of eltrombopag powder for oral suspension (PfOS) and tablet formulations and the effect of a high-calcium meal on eltrombopag pharmacokinetics when administered with or 2 hours before or after PfOS. Clin Ther. 2012;34(3):699–709.
   PubMed Web of Science ®Google Scholar
• Al-Samkari H, Kuter DJ. An alternative intermittent eltrombopag dosing protocol for the treatment of chronic immune thrombocytopenia. Br J Clin Pharmacol. 2018;84(11):2673–2677.
   PubMed Web of Science ®Google Scholar
• Nomoto M, Zamora CA, Schuck E, et al. Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugs. Br J Clin Pharmacol. 2018;84(5):952–960.
   PubMed Web of Science ®Google Scholar
• Bussel JB, Kuter DJ, Aledort LM, et al. A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. Blood. 2014;123(25):3887–3894.
   PubMed Web of Science ®Google Scholar
• Bussel JB, Provan D, Shamsi T, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet Lond Engl. 2009;373(9664):641–648.
   PubMed Web of Science ®Google Scholar
• Cheng G, Saleh MN, Marcher C, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet Lond Engl. 2011;377(9763):393–402.
   PubMed Web of Science ®Google Scholar
• Tomiyama Y, Miyakawa Y, Okamoto S, et al. A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia. J Thromb Haemost JTH. 2012;10(5):799–806.
   PubMed Web of Science ®Google Scholar
• Yang R, Hou M, Li J, et al. Effect of eltrombopag on platelet response and safety results in chinese adults with chronic ITP-primary result of a Phase III study. Blood. 2014;124(21):1464.
   Web of Science ®Google Scholar
• Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet Lond Engl. 2008;371(9610):395–403.
   PubMed Web of Science ®Google Scholar
• Shirasugi Y, Ando K, Miyazaki K, et al. Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized Phase III clinical trial. Int J Hematol. 2011;94(1):71–80.
   PubMed Web of Science ®Google Scholar
• Terrault NA, Hassanein T, Howell CD, et al. Phase II study of avatrombopag in thrombocytopenic patients with cirrhosis undergoing an elective procedure. J Hepatol. 2014;61(6):1253–1259.
   PubMed Web of Science ®Google Scholar
• Dova Pharmaceuticals. A randomized, double-blind, placebo-controlled study with an open-label extension to evaluate the efficacy and safety of avatrombopag for the treatment of chemotherapy-induced thrombocytopenia in subjects with active non-hematological cancers. clinicaltrials.gov; 2020 [cited 2020 Jun 25]. Available from: https://clinicaltrials.gov/ct2/show/NCT03471078
   Google Scholar
• Li C, Li X, Huang F, et al. Efficacy and safety of avatrombopag in patients with thrombocytopenia: a systematic review and meta-analysis of randomized controlled trials. Front Pharmacol. 2019;10:829.
   PubMed Web of Science ®Google Scholar
• Al-Samkari H, Van Cott EM, Kuter DJ. Platelet aggregation response in immune thrombocytopenia patients treated with romiplostim. Ann Hematol. 2019;98(3):581–588.
   PubMed Web of Science ®Google Scholar
• Psaila B, Bussel JB, Linden MD, et al. In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation. Blood. 2012;119(17):4066–4072.
   PubMed Web of Science ®Google Scholar
• Michelson AD, Smolensky Koganov E, Forde EE, et al. Avatrombopag increases platelet count but not platelet activation in patients with thrombocytopenia resulting from liver disease. J Thromb Haemost JTH. 2018;16(12):2515–2519.
   PubMed Web of Science ®Google Scholar
• Afdhal NH, Giannini EG, Tayyab G, et al. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. N Engl J Med. 2012;367(8):716–724.
   PubMed Web of Science ®Google Scholar
• Al-Samkari H, Kuter DJ. Immune thrombocytopenia in adults: modern approaches to diagnosis and treatment. Semin Thromb Hemost. 2020;46(3):275–288.
   PubMed Web of Science ®Google Scholar